AxoGen, Inc. (NASDAQ:AXGN) Short Interest Down 7.3% in December

AxoGen, Inc. (NASDAQ:AXGN) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 1,010,000 shares, a decrease of 7.3% from the November 30th total of 1,090,000 shares. Based on an average daily volume of 356,700 shares, the short-interest ratio is currently 2.8 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $15.00.

Hedge Funds Weigh In On AxoGen

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its position in AxoGen by 2,912.3% during the third quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider’s stock valued at $7,697,000 after purchasing an additional 530,775 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in shares of AxoGen during the third quarter valued at $207,000. Franklin Resources Inc. raised its stake in AxoGen by 9.8% in the 3rd quarter. Franklin Resources Inc. now owns 76,048 shares of the medical equipment provider’s stock worth $1,084,000 after acquiring an additional 6,767 shares during the last quarter. Barclays PLC grew its stake in AxoGen by 119.3% during the 3rd quarter. Barclays PLC now owns 72,036 shares of the medical equipment provider’s stock valued at $1,010,000 after purchasing an additional 39,182 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of AxoGen by 3.2% in the third quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock valued at $14,170,000 after purchasing an additional 31,612 shares during the period. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Stock Down 1.8 %

NASDAQ AXGN traded down $0.29 during trading on Tuesday, reaching $16.20. 135,080 shares of the company’s stock traded hands, compared to its average volume of 390,467. AxoGen has a 12-month low of $5.55 and a 12-month high of $17.23. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The firm has a market cap of $712.93 million, a price-to-earnings ratio of -50.63 and a beta of 1.06. The company’s 50 day simple moving average is $14.25 and its two-hundred day simple moving average is $12.17.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.